<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143167</url>
  </required_header>
  <id_info>
    <org_study_id>RETRAP</org_study_id>
    <secondary_id>2011-002959-34</secondary_id>
    <nct_id>NCT02143167</nct_id>
  </id_info>
  <brief_title>Resistance Training and Amino Pyridine in Multiple Sclerosis</brief_title>
  <acronym>RETRAP</acronym>
  <official_title>RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolonged-release fampridine (SR-fampridine) can improving walking capacity in approximately&#xD;
      40% of MS patients suffering from this by overcoming partly or total conduction block due to&#xD;
      demyelination.&#xD;
&#xD;
      Resistance training has been shown to provide the same kind of benefits for patients by&#xD;
      targeting the muscular component of the motor unit. Thus by combining the two it is likely to&#xD;
      see an synergistic effect.&#xD;
&#xD;
      This trial is designed as a double blind, randomized placebo controlled trial with subsequent&#xD;
      cross-over.&#xD;
&#xD;
      Participants in the two arms will go through the same progressive training program targets at&#xD;
      the lower limbs. For 24 weeks one group receives SR-fampridine and the other receives&#xD;
      placebo. in the the end there is another four weeks of training after cross-over has been&#xD;
      performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle power in the lower limbs</measure>
    <time_frame>Muscle power will be measured after 14 weeks of resistance training.</time_frame>
    <description>Muscle power in the lower limbs is measured by dynamometry pre and post resistance training</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activity</measure>
    <time_frame>Accelerometry is measured after 14 weeks of resistance training</time_frame>
    <description>Activity measured by accelerometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity</measure>
    <time_frame>Walking capacity is measured after 26 weeks of resistance training</time_frame>
    <description>Walking capacity measured by the Six Spot Step Test (SSST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking speed</measure>
    <time_frame>Walking speed is measured after 26 weeks of resistance training</time_frame>
    <description>Walking speed measured by the Timed 25 Foot Walk (T25FW) and the 6-Minute Walking Test (6MWT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capacity in the lower limbs</measure>
    <time_frame>Funcyional capacity in the lower limbs is measured after 26 weeks of resistance training</time_frame>
    <description>Functional capacity measured by the Chair Stand Test (CST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self rated walking capacity</measure>
    <time_frame>Self rated walking capacity is measured after 26 weeks of resistance training</time_frame>
    <description>Self rated walking capacity measured by the 12-Item Multiple Sclerosis Walking Scale (MSWS12)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>SR-fampridine/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of SR-fampridine followed by four weeks of inactive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/SR-fampridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of inactive placebo followed by four weeks of SR-fampridine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR-fampridine</intervention_name>
    <description>One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.&#xD;
The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks.</description>
    <arm_group_label>Placebo/SR-fampridine</arm_group_label>
    <arm_group_label>SR-fampridine/placebo</arm_group_label>
    <other_name>Fampyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo/SR-fampridine</arm_group_label>
    <arm_group_label>SR-fampridine/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with relapsing remitting multiple sclerosis (RRMS), secondary progressive&#xD;
             multiple sclerosis (SPMS) or primary progressive multiple sclerosis (PPMS) fulfilling&#xD;
             the McDonald criteria&#xD;
&#xD;
          -  Expandend Disability Status Scale (EDSS) 3-6.5&#xD;
&#xD;
          -  Pyramidal Functional Score ≥ 2&#xD;
&#xD;
          -  Participants must be able to transport self to gym and to the University of Southern&#xD;
             Denmark&#xD;
&#xD;
          -  Participants must be able to complete T25FW and SSST&#xD;
&#xD;
          -  Fertile female participants are obliged to use hormonal contraceptive measures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of epileptic seizures&#xD;
&#xD;
          -  MS relapse or change in disease modifying treatment (DMT) within 60 days&#xD;
&#xD;
          -  Cancer within five years&#xD;
&#xD;
          -  Blood pressure ≥ 160/100&#xD;
&#xD;
          -  Severe arrhythmia or ischaemic heart disease or unexplained abnormal cardiac&#xD;
             auscultation&#xD;
&#xD;
          -  ≥ ALT 90 U/l, ≥ BSP 210 U/l, ≥ γ-GT 230 U/l&#xD;
&#xD;
          -  GFR &lt; 80 ml/min.&#xD;
&#xD;
          -  History of severe pulmonary disease or unexplained abnormal pulmonary auscultation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Allergy to substances contained in prolonged release Fampridine tablets&#xD;
&#xD;
          -  Concomitant treatment with carvedilol, propranolol or metformin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik B Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sygehus Sønderjylland</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sygehus Lillebælt</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology. 2009 Nov 3;73(18):1478-84. doi: 10.1212/WNL.0b013e3181bf98b4.</citation>
    <PMID>19884575</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240.</citation>
    <PMID>20976768</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.</citation>
    <PMID>19249634</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Henrik Boye Jensen</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

